Related Experiment Video
Updated: Aug 9, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
An assessment of statin safety by hepatologists
David E Cohen1, Frank A Anania, Naga Chalasani
1Division of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. dcohen@partners.org
Abstract:
The purpose of the Liver Expert Panel was to provide advice to the National Lipid Association's (NLA) Safety Task Force in response to specific questions concerning liver-associated risks of statin therapy. The panel was composed of academic hepatologists with clinical and research interests in nonalcoholic fatty liver disease, lipid metabolic disorders, and drug hepatotoxicity.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Cholesterol: Significance and Regulation
Considering cholesterol and...
Hepatic Drug Excretion: Influencing Factors